160 related articles for article (PubMed ID: 37326904)
1. Dual Efficacy of a Catalytic Anti-Oligomeric Aβ42 scFv Antibody in Clearing Aβ42 Aggregates and Reducing Aβ Burden in the Brains of Alzheimer's Disease Mice.
Song C; Li H; Zheng C; Zhang T; Zhang Y
Mol Neurobiol; 2023 Oct; 60(10):5515-5532. PubMed ID: 37326904
[TBL] [Abstract][Full Text] [Related]
2. Synergetic effect of matrine on the catalytic scFv antibody HS72 in vitro and in mice with Alzheimer disease pathology.
Song C; Li H; Zhang T; Zheng C; Zhang Y
Neuropharmacology; 2024 Jan; 242():109775. PubMed ID: 37913984
[TBL] [Abstract][Full Text] [Related]
3. The Mode of Action of an Anti-Oligomeric Amyloid β-Protein Antibody Affects its Protective Efficacy.
Zhang Y; Huai Y; Zhang X; Song C; Cai J; Zhang Y
Neurotox Res; 2019 Feb; 35(2):304-317. PubMed ID: 30229545
[TBL] [Abstract][Full Text] [Related]
4. Novel antibody against oligomeric amyloid-β: Insight into factors for effectively reducing the aggregation and cytotoxicity of amyloid-β aggregates.
Zhang X; Huai Y; Cai J; Song C; Zhang Y
Int Immunopharmacol; 2019 Feb; 67():176-185. PubMed ID: 30553911
[TBL] [Abstract][Full Text] [Related]
5. The protective effects and underlying mechanism of an anti-oligomeric Aβ42 single-chain variable fragment antibody.
Zhang Y; Chen X; Liu J; Zhang Y
Neuropharmacology; 2015 Dec; 99():387-95. PubMed ID: 26256421
[TBL] [Abstract][Full Text] [Related]
6. Aβ42 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer's disease brain extracts.
Sandberg A; Berenjeno-Correa E; Rodriguez RC; Axenhus M; Weiss SS; Batenburg K; Hoozemans JJM; Tjernberg LO; Scheper W
Alzheimers Res Ther; 2022 Dec; 14(1):196. PubMed ID: 36578089
[TBL] [Abstract][Full Text] [Related]
7. Chronic intranasal treatment with an anti-Aβ(30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease.
Cattepoel S; Hanenberg M; Kulic L; Nitsch RM
PLoS One; 2011 Apr; 6(4):e18296. PubMed ID: 21483675
[TBL] [Abstract][Full Text] [Related]
8. Active full-length DNA Aβ
Rosenberg RN; Fu M; Lambracht-Washington D
Alzheimers Res Ther; 2018 Nov; 10(1):115. PubMed ID: 30454039
[TBL] [Abstract][Full Text] [Related]
9. Functional Characteristics and Molecular Mechanism of a New scFv Antibody Against Aβ42 Oligomers and Immature Protofibrils.
Zhang Y; Sun Y; Huai Y; Zhang YJ
Mol Neurobiol; 2015 Dec; 52(3):1269-1281. PubMed ID: 25330935
[TBL] [Abstract][Full Text] [Related]
10. Conformational Essentials Responsible for Neurotoxicity of Aβ42 Aggregates Revealed by Antibodies against Oligomeric Aβ42.
Song C; Zhang T; Zhang Y
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235284
[TBL] [Abstract][Full Text] [Related]
11. A conformation-specific antibody against oligomeric β-amyloid restores neuronal integrity in a mouse model of Alzheimer's disease.
He P; Schulz P; Sierks MR
J Biol Chem; 2021; 296():100241. PubMed ID: 33376140
[TBL] [Abstract][Full Text] [Related]
12. Amyloid-β 1-24 C-terminal truncated fragment promotes amyloid-β 1-42 aggregate formation in the healthy brain.
Mazzitelli S; Filipello F; Rasile M; Lauranzano E; Starvaggi-Cucuzza C; Tamborini M; Pozzi D; Barajon I; Giorgino T; Natalello A; Matteoli M
Acta Neuropathol Commun; 2016 Oct; 4(1):110. PubMed ID: 27724899
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a Conformation-Restricted Amyloid β Peptide and Immunoreactivity of Its Antibody in Human AD brain.
Kageyama Y; Irie Y; Matsushima Y; Segawa T; Bellier JP; Hidaka K; Sugiyama H; Kaneda D; Hashizume Y; Akatsu H; Miki K; Kita A; Walker DG; Irie K; Tooyama I
ACS Chem Neurosci; 2021 Sep; 12(18):3418-3432. PubMed ID: 34464082
[TBL] [Abstract][Full Text] [Related]
14. Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.
Bruckmann S; Brenn A; Grube M; Niedrig K; Holtfreter S; von Bohlen und Halbach O; Groschup M; Keller M; Vogelgesang S
Curr Alzheimer Res; 2017; 14(6):656-667. PubMed ID: 27915995
[TBL] [Abstract][Full Text] [Related]
15. Aβ43 aggregates exhibit enhanced prion-like seeding activity in mice.
Ruiz-Riquelme A; Mao A; Barghash MM; Lau HHC; Stuart E; Kovacs GG; Nilsson KPR; Fraser PE; Schmitt-Ulms G; Watts JC
Acta Neuropathol Commun; 2021 May; 9(1):83. PubMed ID: 33971978
[TBL] [Abstract][Full Text] [Related]
16. The conformational epitope for a new Aβ42 protofibril-selective antibody partially overlaps with the peptide N-terminal region.
Colvin BA; Rogers VA; Kulas JA; Ridgway EA; Amtashar FS; Combs CK; Nichols MR
J Neurochem; 2017 Dec; 143(6):736-749. PubMed ID: 28881033
[TBL] [Abstract][Full Text] [Related]
17. Dual-targeted magnetic mesoporous silica nanoparticles reduce brain amyloid-β burden via depolymerization and intestinal metabolism.
Liu N; Liang X; Yang C; Hu S; Luo Q; Luo H
Theranostics; 2022; 12(15):6646-6664. PubMed ID: 36185606
[No Abstract] [Full Text] [Related]
18. Naturally occurring autoantibodies against Aβ oligomers exhibited more beneficial effects in the treatment of mouse model of Alzheimer's disease than intravenous immunoglobulin.
Wang T; Xie XX; Ji M; Wang SW; Zha J; Zhou WW; Yu XL; Wei C; Ma S; Xi ZY; Pang GL; Liu RT
Neuropharmacology; 2016 Jun; 105():561-576. PubMed ID: 26907803
[TBL] [Abstract][Full Text] [Related]
19. Dual-Emission GFP Chromophore-Based Derivative for Imaging and Discriminating Aβ Oligomers and Aggregates.
Leng H; Wang Y; Wang J; Sun H; Sun A; Pistolozzi M; Zhang L; Yan J
Anal Chem; 2022 Feb; 94(4):1999-2006. PubMed ID: 35041386
[TBL] [Abstract][Full Text] [Related]
20. Prion-like propagation of β-amyloid aggregates in the absence of APP overexpression.
Ruiz-Riquelme A; Lau HHC; Stuart E; Goczi AN; Wang Z; Schmitt-Ulms G; Watts JC
Acta Neuropathol Commun; 2018 Apr; 6(1):26. PubMed ID: 29615128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
